

AUSTRALIAN PRODUCT INFORMATION – FLUCON (FLUOROMETHOLONE) EYE DROPS SUSPENSION

1 NAME OF THE MEDICINE

Fluorometholone.

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each mL of FLUCON contains fluorometholone 1.0 mg

List of excipients with known effect: benzalkonium chloride 0.1 mg as preservative

For the full list of excipients, see Section 6.1 LIST OF EXCIPIENTS.

3 PHARMACEUTICAL FORM

Eye drops, suspension. It is a sterile ophthalmic suspension.

4 CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS

For steroid responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.

4.2 DOSE AND METHOD OF ADMINISTRATION

Shake well before use.

One or two drops instilled into the conjunctival sac two to four times daily. During the initial 24 to 48 hours the dosage may be safely increased to 2 drops every hour. Care should be taken not to discontinue therapy prematurely.

4.3 CONTRAINDICATIONS

- Acute, untreated bacterial infections.
- Herpes simplex keratitis.
- Fungal diseases of ocular structures.
- Vaccinia, varicella and most other viral diseases of the cornea and conjunctiva.
- Tuberculosis of the eye.
- Hypersensitivity to the constituents of this medication.
- Mycobacterial ocular infections.

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Identified precautions

Employment of steroid medication in the treatment of stromal keratitis or uveitis caused by herpes simplex requires great caution; frequent slit lamp microscopy is mandatory. Prolonged use may result in ocular hypertension and/or glaucoma, damage to the optic nerve, defects in visual acuity

and visual field, posterior subcapsular cataract formation. Corticosteroids may reduce resistance to and aid in the establishment of bacterial, viral or fungal secondary ocular infection from pathogens liberated from ocular tissue. In those diseases causing thinning of the cornea, or sclera, perforation has been known to occur with the use of topical steroids. Acute untreated infection may be masked or enhanced by steroid medication.

Topical ophthalmic corticosteroids may slow corneal wound healing. Topical NSAIDs are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems. (See Section 4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS).

As fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid applications, fungus invasion must be suspected in any persistent corneal ulceration where a steroid has been used or is in use and corticosteroids therapy should be discontinued if fungal infection occurs.

In patients receiving ophthalmic corticosteroid therapy intraocular pressure should be checked regularly. This is especially important in paediatric patients, as the risk of corticosteroid induced ocular hypertension may be greater in children and may occur earlier than in adults. FLUCON is not approved for use in paediatric patients. The risk of corticosteroid-induced raised intraocular pressure and/or cataract formation is increased in predisposed patients (e.g. diabetes).

Systemic corticosteroid side-effects may occur after intensive or long-term continuous ophthalmic corticosteroid therapy in predisposed patients, including children and patients treated with CYP3A4 inhibitors (e.g. ritonavir and cobicistat).

Visual Disturbance

Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.

Contact Lenses

No contact lenses should be worn under FLUCON treatment. Additionally, this product contains benzalkonium chloride which may cause irritation and is known to discolour soft contact lenses.

Use in the elderly

No data available.

Paediatric use

In patients receiving ophthalmic corticosteroid therapy intraocular pressure should be checked regularly. This is especially important in paediatric patients, as the risk of corticosteroid induced ocular hypertension may be greater in children and may occur earlier than in adults. FLUCON is not approved for use in paediatric patients.

Effects on laboratory tests

No data available.

4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

Concomitant use of topical steroids and topical NSAIDs may increase the potential for corneal healing problems.

Co-treatment with CYP3A4 inhibitors, including ritonavir and cobicistat, may increase systemic exposure resulting in increased risk of systematic side-effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side-effects, in which case patients should be monitored for systemic corticosteroid side-effects.

4.6 FERTILITY, PREGNANCY AND LACTATION

Effects on fertility

There are no data regarding the effects of FLUCON Eye Drops on male or female fertility.

Use in pregnancy – Pregnancy Category B3

There are no or limited amount of data from the use of FLUCON Eye Drops in pregnant women. Animal studies with corticosteroids have shown reproductive toxicity. FLUCON Eye Drops is not recommended during pregnancy and in women of childbearing potential not using contraception.

Use in lactation

There is insufficient information on whether fluorometholone and its metabolites from FLUCON Eye Drops are excreted in human milk. Systemic corticosteroids are excreted into human milk. A risk to the suckling child cannot be excluded. Because of the potential for serious adverse reactions in nursing infants from fluorometholone, use only when considered essential by the physician.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

Temporary blurred vision or other visual disturbances may affect the ability to drive or use machines. If blurred vision occurs at instillation, the patient must wait until the vision clears before driving or using machinery.

4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

Glaucoma with optic nerve damage, visual acuity or field defects, posterior subcapsular cataract formation, secondary ocular infection from pathogens liberated from ocular tissue, perforation of the globe.

Post Marketing Experience

The following adverse reactions have been reported following use of fluorometholone topical ophthalmic preparations. Frequencies cannot be estimated from the available data. Adverse reactions are presented in order of decreasing seriousness.

Eye Disorders

Intraocular pressure increased, vision blurred (see Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE), eye pain, ocular discomfort, foreign body sensation in eyes, eye irritation, ocular hyperaemia, lacrimation increased.

Gastrointestinal Disorders

Dysgeusia.

Reporting suspected adverse effects

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 OVERDOSE

An ocular overdose of FLUCON Eye Drops is not likely to be associated with toxicity. Accidental ingestion is also unlikely to be associated with toxicity. Treatment of suspected ingestion should be symptomatic and supportive.

For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

Pharmacotherapeutic group: ophthalmological, anti-inflammatory agents, corticosteroids. ATC code: S01BA07.

Mechanism of action

Inhibition of the inflammatory response to inciting agents of mechanical, chemical or immunological nature. No generally accepted explanation of the steroid property has been advanced. Adrenocorticosteroids and their derivatives are capable of producing a rise in intraocular pressure.

Clinical trials

In clinical studies on patients' eyes treated with both dexamethasone and fluorometholone, fluorometholone demonstrated a lower propensity to increase intraocular pressure than did dexamethasone.

5.2 PHARMACOKINETIC PROPERTIES

No data available.

5.3 PRECLINICAL SAFETY DATA

Genotoxicity

No data available.

Carcinogenicity

No data available.

6 PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS

Benzalkonium chloride, sodium phosphate monobasic, sodium phosphate dibasic anhydrous, polysorbate 80, sodium chloride, disodium edetate, polyvinyl alcohol, hypromellose and purified water.

6.2 INCOMPATIBILITIES

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 SHELF LIFE

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 SPECIAL PRECAUTIONS FOR STORAGE

Store at or below 25°C. Do not refrigerate or freeze.

Discard container 4 weeks after opening.

6.5 NATURE AND CONTENTS OF CONTAINER

As a sterile suspension in 5 mL plastic DROP-TAINER™ dispensers.


6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 PHYSICOCHEMICAL PROPERTIES

Chemical structure

Its chemical name is pregna-1,4-diene-3,20-dione,9-fluoro-11,17-dihydroxy-6-methyl(6 α ,11 β). The chemical structure of fluorometholone is presented below:



Fluorometholone has a molecular formula of C₂₂H₂₉FO₄ and its molecular weight is 376.5.

CAS number

426-13-1

7 MEDICINE SCHEDULE (POISONS STANDARD)

Prescription Only Medicine (Schedule 4)

8 SPONSOR

Novartis Pharmaceuticals Pty Limited

ABN 18 004 244 160

54 Waterloo Rd

Macquarie Park NSW 2113

(02) 9805 3555

<http://www.novartis.com.au>**9 DATE OF FIRST APPROVAL**

15 October 1991

10 DATE OF REVISION

14 September 2018

SUMMARY TABLE OF CHANGES

Section Changed	Summary of new information
All	SmPC format
4.4	Precautions about long term use of ophthalmic corticosteroid use.
4.4	Include visual disturbance following corticosteroid use as a precaution.
4.5	Addition of CYP3A4 inhibitors, including ritonavir and cobicistat

Internal document code
(flu140918i based on CDS 2 March 2018)